Abstract:
A DTD-compliant XML document editor is disclosed. The XML document editor generates hints for required elements and required element slots automatically in the process of document creation and edition so as to guide the user to produce a valid document, while syntactic violations are avoided at the same time. The editor also suggests optional elements that may be added into the document to be edited. The user requires no knowledge about XML and DTD to edit DTD-compliant XML documents. The editing process is user-interface-neutral, being able to support user interfaces based on tree views, presentation views and forms. By combining the DTD-compliant editing process with the simplicity of forms, a simple XML document editor with forms as its user interface is developed.
Abstract:
This document describes compounds, extracts, and pharmaceutical compositions relating to Gastrodia spp., and methods for the treatment subjects having metabolic disorders or medical conditions such as Huntington's disease, a trinucleotide repeat disease or abnormal blood glucose levels.
Abstract:
A method of cross-linking a peptide to form a homopolymer of the peptide, to immobilize the peptide on a solid phase and to enhance antigenicity of the peptide is disclosed. The method comprises the steps of preparing a fusion peptide by incorporating a cross-linking segment including a tetrapeptide sequence Q-X-K-(S/T) (SEQ ID NO: 15) into the peptide and cross-linking the peptide by a glutaminase.
Abstract translation:公开了将肽交联以形成肽的均聚物的方法,以将肽固定在固相上并增强肽的抗原性。 该方法包括通过将包含四肽序列Q-X-K-(S / T)(SEQ ID NO:15)的交联链段并入肽中并通过谷氨酰胺酶交联肽来制备融合肽的步骤。
Abstract:
An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.
Abstract:
This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).
Abstract:
This document describes compounds, extracts, and pharmaceutical compositions relating to Gastrodia spp., and methods for the treatment subjects having metabolic disorders or medical conditions such as Huntington's disease, a trinucleotide repeat disease or abnormal blood glucose levels.
Abstract:
A nucleic acid containing a glutelin gene promoter. Disclosed are transformed plant cells and transgenic plants containing a nucleic acid that includes the promoter operably linked to a sequence encoding heterologous protein. Also disclosed are methods of making the transformed plant cells and transgenic plants and methods for expressing a polypeptide.
Abstract:
The present invention provides a method utilizing mammalian expression system for generating virus-like particles (VLPs) of mammalian-hosted viruses, particularly SARS-CoV. The method of the present invention involves expression of viral structural proteins in Vero cells and thereby obtaining recombinant VLPs in the culture medium. SARS-VLPs generated by the method of the present invention are highly immunogenic and can elicit not only humoral but also cellular immune responses in a mammal.
Abstract:
A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor/blood ratio of the polyethylene glycol containing compound.
Abstract:
This invention relates to predicting a patient's warfarin dose based on the nucleotide at position −1639 of the VKORC1 gene and the genotype of the CYP2C9 gene in that patient. The warfarin dose so predicted can be further adjusted according to the patient's non-genetic factors, e.g., age, body surface area, medical conditions, and use or non-use of certain drugs.